Alexander Smith

Alexander Smith’s Profile

Biotech merger volumes down but deals numbers booming

July 24, 2009

An interesting snippet from the weekly Thomson Reuters Investment Banking Scorecard.

While the value of M&A deals in the biotech sector has fallen sharply year-on-year — largely because of the disproportionate impact of Roche’s takeover of Genentech last year — the number of deals done is actually up, by 15 percent.

Bristol-Myers Squibb’s $1.9 billion acquisition of Medarex has lifted the volume to $5.3 billion for year-to-date 2009.

That’s a 90 percent decrease from 2008 levels.

But if you exclude Roche’s $46.7 billion acquisition of Genentech, biotech M&A volume is down just 22 percent over 2008 levels.

More good news for JP Morgan and Goldman Sachs who top the advisor rankings in the sector.

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
  • About Alexander

    "I am a Reuters columnist specialising in financial services -- particularly investment banking, M&A and corporate finance. I am based in London, but have lived and worked in Spain and South America. I have been a journalist and editor for almost 19 years and before moving into commentary at the beginning of 2009 I was the editor responsible for Reuters coverage of company news in Europe, Middle East and Africa."
  • More from Alexander

  • Follow Alexander